A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2015
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 09 Mar 2010 Novartis Vaccines added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 16 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 09 Nov 2006 New trial record.